* . *
  • About
  • Advertise
  • Privacy & Policy
  • Contact
Wednesday, June 11, 2025
Earth-News
  • Home
  • Business
  • Entertainment
    The Analyst Verdict: PENN Entertainment In The Eyes Of 7 Experts – Nasdaq

    7 Experts Reveal the Ultimate Verdict on PENN Entertainment

    3 Arts Entertainment Expands Into News With Acquisition of OManagement (Exclusive) – The Hollywood Reporter

    3 Arts Entertainment Expands Into News With Acquisition of OManagement (Exclusive) – The Hollywood Reporter

    Leading Proxy Advisory Firm Glass Lewis Recommends Shareholders Vote “FOR” Both of PENN Entertainment’s Director Nominees on the WHITE Proxy Card – Business Wire

    Glass Lewis Urges Shareholders to Support All PENN Entertainment Director Nominees on the WHITE Proxy Card

    Cisco Partners with Monumental Sports & Entertainment to Power New D.C. Arena – Cisco Newsroom

    Cisco Teams Up with Monumental Sports & Entertainment to Revolutionize the New D.C. Arena Experience

    Middle Eastern Entertainment Headlines at 5:49 a.m. GMT – Yahoo

    Exciting Updates from the Middle Eastern Entertainment Scene!

    Ceramic Dalmatian Entertainment is WLAF’s Business of the Week – WLAF

    Spotlight on Success: Ceramic Dalmatian Entertainment Shines as This Week’s Featured Business!

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    Russian Scientists Develop Sub-Ångström Technology for Next-Gen Quantum Processors – The Quantum Insider

    Russian Scientists Pioneer Sub-Ångström Technology to Revolutionize Next-Gen Quantum Processors

    Study uncovers SiPore Technology’s capacity to regulate blood glucose levels – Nutraceutical Business Review

    Study uncovers SiPore Technology’s capacity to regulate blood glucose levels – Nutraceutical Business Review

    SunHydrogen Unveils Large Hydrogen Reactor in Houston – Fuel Cells Works

    SunHydrogen Launches Groundbreaking Large-Scale Hydrogen Reactor in Houston

    Technology, Labor Rights, and Political Power in Kenya and Across Africa – Tech Policy Press

    How Technology is Shaping Labor Rights and Political Power Across Africa

    Reeves to Announce £86 Billion for Science and Technology in Spending Review – Bloomberg

    Reeves Set to Unveil Groundbreaking £86 Billion Investment in Science and Technology!

    Innovation at Scale: How P&G Transforms Business Through Technology – Procter & Gamble

    Revolutionizing Business: P&G’s Bold Journey into Technological Innovation

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
  • Home
  • Business
  • Entertainment
    The Analyst Verdict: PENN Entertainment In The Eyes Of 7 Experts – Nasdaq

    7 Experts Reveal the Ultimate Verdict on PENN Entertainment

    3 Arts Entertainment Expands Into News With Acquisition of OManagement (Exclusive) – The Hollywood Reporter

    3 Arts Entertainment Expands Into News With Acquisition of OManagement (Exclusive) – The Hollywood Reporter

    Leading Proxy Advisory Firm Glass Lewis Recommends Shareholders Vote “FOR” Both of PENN Entertainment’s Director Nominees on the WHITE Proxy Card – Business Wire

    Glass Lewis Urges Shareholders to Support All PENN Entertainment Director Nominees on the WHITE Proxy Card

    Cisco Partners with Monumental Sports & Entertainment to Power New D.C. Arena – Cisco Newsroom

    Cisco Teams Up with Monumental Sports & Entertainment to Revolutionize the New D.C. Arena Experience

    Middle Eastern Entertainment Headlines at 5:49 a.m. GMT – Yahoo

    Exciting Updates from the Middle Eastern Entertainment Scene!

    Ceramic Dalmatian Entertainment is WLAF’s Business of the Week – WLAF

    Spotlight on Success: Ceramic Dalmatian Entertainment Shines as This Week’s Featured Business!

  • General
  • Health
  • News

    Cracking the Code: Why China’s Economic Challenges Aren’t Shaking Markets, Unlike America’s” – Bloomberg

    Trump’s Narrow Window to Spread the Truth About Harris

    Trump’s Narrow Window to Spread the Truth About Harris

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    Israel-Gaza war live updates: Hamas leader Ismail Haniyeh assassinated in Iran, group says

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    PAP Boss to Niger Delta Youths, Stay Away from the Protest

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Court Restricts Protests In Lagos To Freedom, Peace Park

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Fans React to Jazz Jennings’ Inspiring Weight Loss Journey

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • Science
  • Sports
  • Technology
    Russian Scientists Develop Sub-Ångström Technology for Next-Gen Quantum Processors – The Quantum Insider

    Russian Scientists Pioneer Sub-Ångström Technology to Revolutionize Next-Gen Quantum Processors

    Study uncovers SiPore Technology’s capacity to regulate blood glucose levels – Nutraceutical Business Review

    Study uncovers SiPore Technology’s capacity to regulate blood glucose levels – Nutraceutical Business Review

    SunHydrogen Unveils Large Hydrogen Reactor in Houston – Fuel Cells Works

    SunHydrogen Launches Groundbreaking Large-Scale Hydrogen Reactor in Houston

    Technology, Labor Rights, and Political Power in Kenya and Across Africa – Tech Policy Press

    How Technology is Shaping Labor Rights and Political Power Across Africa

    Reeves to Announce £86 Billion for Science and Technology in Spending Review – Bloomberg

    Reeves Set to Unveil Groundbreaking £86 Billion Investment in Science and Technology!

    Innovation at Scale: How P&G Transforms Business Through Technology – Procter & Gamble

    Revolutionizing Business: P&G’s Bold Journey into Technological Innovation

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
No Result
View All Result
Earth-News
No Result
View All Result
Home Health

Can a GLP-1 Agonist Improve Parkinson’s Symptoms?

December 20, 2023
in Health
Can a GLP-1 Agonist Improve Parkinson’s Symptoms?
Share on FacebookShare on Twitter

An investigational brain-penetrant, pegylated analogue of the glucagon-like peptide-1 (GLP-1) receptor agonist exenatide (Byetta, Bydureon) known as NLY01 did not lead to improvement in Parkinson’s disease symptoms compared with placebo, a phase II trial showed.

Neither 2.5 mg or 5.0 mg of weekly NLY01 injections showed any difference from placebo in the sum of Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) parts II and III scores at 36 weeks, according to Andrew McGarry, MD, of Rowan University in Camden, New Jersey, and colleagues.

Compared with placebo, the difference at 36 weeks was -0.39 (95% CI -2.96 to 2.18, P=0.77) for 2.5 mg and 0.6 (-2.28 to 3.00, P=0.79) for 5.0 mg, McGarry and co-authors reported in Lancet Neurology.

However, a subgroup analysis suggested the possibility of motor benefit in participants under age 60, the researchers said.

The GLP-1 receptor is present in the brain, and agonist activity is thought to be anti-inflammatory by reducing microglia activation. Exenatide is a GLP-1 receptor agonist approved to treat type 2 diabetes.

“In a database of more than 100,000 individuals with diabetes, those using GLP-1 receptor agonists had a 62% lower risk of developing Parkinson’s disease,” McGarry and colleagues pointed out. In 2017, a single-center trial showed that exenatide had positive effects on Parkinson’s motor scores that continued beyond the period of exposure.

People with type 2 diabetes have an increased risk of Parkinson’s disease, particularly those with early diabetes onset (ages 25-44) and a low BMI (below 18.5), noted Claudia Trenkwalder, MD, and Brit Mollenhauer, MD, of the University Medical Center Göttingen in Germany, in an accompanying editorial.

“The Parkinson’s disease course can be faster and more severe for individuals with type 2 diabetes than for those without type 2 diabetes, and it can be characterized by motor fluctuations in response to treatment occurring earlier and a more rapid decline in cognitive function,” Trenkwalder and Mollenhauer wrote.

Trials like the NLY01 phase II study that investigate the preventive potential of existing drugs are urgently needed, the editorialists observed.

“One strategy to move forward with GLP-1 agonists could be to better select the participants with Parkinson’s disease — e.g., young people with high inflammatory activity who would benefit most from the targeted metabolic and inflammatory mechanism of GLP-1 agonism,” they suggested.

“In addition to carefully selecting participants at an appropriate disease stage, improvements to the design of studies in people with established Parkinson’s disease need to be pursued,” they added.

McGarry and co-authors randomized 255 people with early untreated Parkinson’s disease to subcutaneous 2.5 mg or 5.0 mg NLY01, or placebo (85 people in each group). Participants were told to administer the drug or placebo once a week for 36 weeks. Mean age was 61.5 and more than half of participants were men.

The primary efficacy endpoint was change from baseline to week 36 in the sum of MDS-UPDRS parts II and III scores. Part II assesses motor aspects of experiences of daily living and part III is a motor examination. Each MDS-UPDRS subscale has a rating from 0 (normal) to 4 (severe).

Secondary endpoints included MDS-UPDRS part I scores (non-motor aspects of experiences of daily living), clinical and patient impressions of severity, cognitive test scores, and dopamine transporter imaging parameters. No secondary endpoint differed from placebo at either dose.

NLY101 was generally safe and well tolerated. Gastrointestinal disorders emerged in 61% of the 2.5-mg dose group and 75% of the 5.0-mg group, most frequently nausea.

Participants under age 60 showed nominally significant reductions from baseline in the sum of MDS-UPDRS parts II and III scores at 36 weeks compared with placebo, “a finding that could be driven in part by a greater decline in the younger placebo group,” McGarry and colleagues acknowledged. “Further studies should look to test a younger population for potentially better treatment outcomes.”

The phase II trial may have been too short to see effects clearly, the researchers noted. Exenatide-PD3, a phase III, 2-year study of exenatide in 200 people with mild-to-moderate Parkinson’s disease on standard treatment, is underway; results are expected in 2024.

Judy George covers neurology and neuroscience news for MedPage Today, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more. Follow

Disclosures

Funding for the study came from D&D Pharmatech-Neuraly.

McGarry and several co-authors received salary support from Neuraly for their work on the study. Other co-authors were either Neuraly employees, employees of the contract research organization, or received research support from Neuraly. One co-author received stock and equity in D&D Pharmatech.

Editorialists reported relationships with General Electric Healthcare, Bial, Roche, Biogen, AbbVie, Amprion, the Michael J. Fox Foundation for Parkinson’s Research, Aligning Science Across Parkinson’s, AbbVie, Boehringer, Britannia, Ono, Convatec, UCB, Alexion, EU Horizon 2020, ERA-NET BRAVA, and the International Parkinson and Movement Disorder Society.

Primary Source

Lancet Neurology

Source Reference: McGarry A, et al “Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson’s disease: a randomized, double-blind, placebo-controlled trial” Lancet Neurol 2024; DOI: 10.1016/S1474-4422(23)00378-2.

Secondary Source

Lancet Neurology

Source Reference: Trenkwalder C and Mollenhauer B “The long road to neuroprotection for Parkinson’s disease” Lancet Neurol 2024; DOI: 10.1016/S1474-4422(23)00462-3.

>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : MedPageToday – https://www.medpagetoday.com/neurology/parkinsonsdisease/107945

Tags: Agonisthealthimprove
Previous Post

Explanations Don’t Help Clinicians Spot Biased AI

Next Post

Clinical Challenges: Managing Pediatric Crohn’s Disease

Two major ecological shifts shaped 60 million years of ungulate faunal evolution – Nature

How Two Major Ecological Shifts Transformed 60 Million Years of Ungulate Evolution

June 11, 2025
Letter: Cutting funding for science research will have far-reaching consequences – InForum

Letter: Cutting funding for science research will have far-reaching consequences – InForum

June 11, 2025
Whitesides says budget proposal shows the administration does not value NASA science – SpaceNews

Whitesides Slams Budget Proposal for Undermining NASA Science

June 11, 2025
Lifestyle publishers rewrite the SEO playbook for AI-driven search – Digiday

Lifestyle publishers rewrite the SEO playbook for AI-driven search – Digiday

June 11, 2025

David Squires on … Infantino’s Club World Cup buildup in the land of Trump – The Guardian

June 11, 2025
America must lead on the gig economy — or others will set the rules – Washington Examiner

America must lead on the gig economy — or others will set the rules – Washington Examiner

June 11, 2025
The Analyst Verdict: PENN Entertainment In The Eyes Of 7 Experts – Nasdaq

7 Experts Reveal the Ultimate Verdict on PENN Entertainment

June 11, 2025
Amarillo breaks ground on psychiatric hospital, part of the state’s $1.5B investment in mental health – The Texas Tribune

Amarillo Unveils State-of-the-Art Psychiatric Hospital in Texas’ $1.5 Billion Mental Health Expansion

June 11, 2025
Smithsonian says it’s committed to being free from ‘partisan influence’ after Trump tries to remove gallery director – CNN

Smithsonian Vows to Stay Independent After Trump Attempts to Oust Gallery Director

June 11, 2025
Russian Scientists Develop Sub-Ångström Technology for Next-Gen Quantum Processors – The Quantum Insider

Russian Scientists Pioneer Sub-Ångström Technology to Revolutionize Next-Gen Quantum Processors

June 11, 2025

Categories

Archives

June 2025
MTWTFSS
 1
2345678
9101112131415
16171819202122
23242526272829
30 
« May    
Earth-News.info

The Earth News is an independent English-language daily published Website from all around the World News

Browse by Category

  • Business (20,132)
  • Ecology (681)
  • Economy (695)
  • Entertainment (21,600)
  • General (15,323)
  • Health (9,737)
  • Lifestyle (699)
  • News (22,149)
  • People (696)
  • Politics (702)
  • Science (15,912)
  • Sports (21,196)
  • Technology (15,681)
  • World (680)

Recent News

Two major ecological shifts shaped 60 million years of ungulate faunal evolution – Nature

How Two Major Ecological Shifts Transformed 60 Million Years of Ungulate Evolution

June 11, 2025
Letter: Cutting funding for science research will have far-reaching consequences – InForum

Letter: Cutting funding for science research will have far-reaching consequences – InForum

June 11, 2025
  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

No Result
View All Result

© 2023 earth-news.info

Go to mobile version